GlycoNex - Asset Resilience Ratio
GlycoNex (4168) has an Asset Resilience Ratio of 11.31% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read GlycoNex total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how GlycoNex's Asset Resilience Ratio has changed over time. See GlycoNex (4168) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down GlycoNex's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see GlycoNex (4168) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$175.60 Million | 11.31% |
| Total Liquid Assets | NT$175.60 Million | 11.31% |
Asset Resilience Insights
- Moderate Liquidity: GlycoNex has 11.31% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
GlycoNex Industry Peers by Asset Resilience Ratio
Compare GlycoNex's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for GlycoNex (2017–2024)
The table below shows the annual Asset Resilience Ratio data for GlycoNex.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 25.26% | NT$332.60 Million ≈ $10.48 Million |
NT$1.32 Billion ≈ $41.48 Million |
-10.18pp |
| 2023-12-31 | 35.44% | NT$550.31 Million ≈ $17.34 Million |
NT$1.55 Billion ≈ $48.92 Million |
+0.69pp |
| 2022-12-31 | 34.75% | NT$596.58 Million ≈ $18.80 Million |
NT$1.72 Billion ≈ $54.09 Million |
+19.94pp |
| 2021-12-31 | 14.80% | NT$206.53 Million ≈ $6.51 Million |
NT$1.40 Billion ≈ $43.95 Million |
-5.92pp |
| 2020-12-31 | 20.72% | NT$326.22 Million ≈ $10.28 Million |
NT$1.57 Billion ≈ $49.59 Million |
+16.09pp |
| 2019-12-31 | 4.63% | NT$61.70 Million ≈ $1.94 Million |
NT$1.33 Billion ≈ $41.97 Million |
-1.22pp |
| 2018-12-31 | 5.85% | NT$91.32 Million ≈ $2.88 Million |
NT$1.56 Billion ≈ $49.21 Million |
-1.55pp |
| 2017-12-31 | 7.40% | NT$138.06 Million ≈ $4.35 Million |
NT$1.87 Billion ≈ $58.80 Million |
-- |
About GlycoNex
GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. The company's development pipeline for the treatment of solid tumors includes GNX102, a humanized monoclonal antibody, currently under phase 1 clinical stage; GNX201, an antibody drug currently under preclinical stage; GNX203, glycan-directed anti… Read more